New antidepressants;Neue antidepressiva

Aktuelle Neurologie

Volumn 27, Issue 3, 2000, Pages 132-137

  Mirzaian, Ervand ^a   Gastpar, M ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DEPRESSION; DRUG EFFICACY; NEUROBIOLOGY; SEROTONIN BLOOD LEVEL; SEROTONIN SYNDROME;

EID: 0034098119     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1017534     Document Type: Article

References (44)

1. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994; 55 (Suppl A): 6-221
2. Preskorn SH. Klinische Pharmakologie der selektiven Serotonin-Wiederaufnahmehemmer. Caddo, USA: Professional Communications Inc, 1997
3. Benkert O, Hippius H. Kompendium der psychiatrischen Pharmakotherapie. Berlin: Springer, 1998
4. Demling J, Ebert D, Laux D et al. Klinik In: Rieder P, Laux G, Pöldinger W (Hrsg): Neuropsychopharmaka, Band III. Wien · New York: Springer, 1993: 127-185
5. Beasley CM, Dornseif BE, Bosomworth JC et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br Med J 1991; 303: 685-692
6. Wagner W, Plekkenpol B, Gray TE et al. Review of fluvoxamine safety database. Drugs 1992; 43 (Suppl 2): 48-54
7. Ahrens B, Maier W. Akuttherapie. In: Gastpar M (Hrsg): Antidepressiva. Stuttgart · New York: Thieme, 1998: 57-67
8. Danish University Antidepressant Group. Paroxetine: a selective serotonin re-uptake inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18: 289-299
9. nd ed. Chichester: John Wiley & Sons, 1996: 155-178
10. nd ed. Chichester: John Wiley & Sons, 1996: 135-153
11. Benkert O, Hippius H. Psychiatrische Pharmakotherapie. 6. Auflage Berlin: Springer, 1998
12. Armitage R, Yonkers K, Cole D et al. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 1997; 17: 161-168
13. Feiger JA, Kiev A, Shrivastava RK et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual functions and satisfaction. J Clin Psychiatry 1996; 57 (Suppl 2): 53-62
14. Cohn CK, Robinson DS, Roberts DL et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996; 57 (Suppl 2): 15-18
15. Davis R, Whittington R, Bryson HM. Nefazodone - a review of it's pharmacology and clinical efficacy in the management of major depression. Drugs 1997; 53: 608-636
16. Feighner J, Targum SD, Bennet ME et al. Eine doppel-blinde, plazebo-überprüfte Studie über die Anwendung von Nefazodon bei Patienten, die wegen Major Depression stationär behandelt werden. J Clin Psychiatry 1998; 59: 246-253
17. Marcus RN, Mendels J. Nefazodone in the treatment of severe, melancholic, and recurrent depression. J Clin Psychiatry 1996; 57 (Suppl 2): 19-23
18. Rickels K, Schweizer E, Clary C et al. Nefazodone and imipramine in major depression. A placebo-controlled trial. Brit J Psychiatry 1994; 164: 802-805
19. Ballenger JC. Clinical evaluation of venlafaxine. J Clin Psychopharmacol 1996; 16 (Suppl 2): 29-36
20. Holliday SM, Benfield P. Venlafaxine: A review of its pharmacological and therapeutic potential in depression. Drugs 1995; 49: 280-294
21. Benkert O, Grunder G, Wetzel H et al. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996; 30: 441-451
22. Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol 1996; 16 (Suppl 2): 21-27
23. Rudolph RL, Derivan AT. The safety and tolerability of Venlafaxine Hydrochloride: Analysis of the clinical trials database. J Clin Psychopharmacol 1996; 16 (Suppl 2): 54-59
24. Wheatley DP, van Moffaert M, Timmerman L et al. Mirtazapin: Wirksamkeit und Verträglichkeit im Vergleich mit Fluoxetin bei Patienten mit mittelschwerer bis schwerer Depression. J Clin Psychiatry 1998; 59: 306-312
25. Bruijn JA, Moleman P, Mulder PG et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology 1996; 127: 231-237
26. Kasper S, Zivkov M, Roes KC et al. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol 1997; 7: 115-124
27. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 63-73
28. Richou H, Ruimy P, Charbaut H et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Human Psychopharmacol 1995; 10: 263-271
29. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 (Suppl 4): 37-45
30. Berzewski H, van Moffaert M, Gagiano C. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients from major depressive episodes. Eur Neuropsychopharmacol 1997; 7, Suppl 1: 37-47
31. Massana J. Reboxetine versus Fluoxetine: An overview of efficacy and tolerability. J Clin Psychiatry 1998; 59 (Suppl): 9-15
32. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997; 11 (Suppl 4): 17-23
33. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997; 11 (Suppl 4): 33-37
34. Amrein R, Stabl M, Henauer S et al. Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview. Can J Psychiatry 1997; 42: 1043-1050
35. Bakish D, Wiens A, Ellis J et al. A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression. Canad J Psychiatry 1992; 37 (Suppl 1): 12-17
36. Baumhackl U, Biziere K, Fischbach R et al. Efficacy and tolerability of moclobemide compared with imipramine in the treatment of major depressive disorder (DSM-III): an Austrian double-blind multicenter study. Br J Psychiatry 1989; 155 (Suppl 6): 78-83
37. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998; 12: 482-491
38. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome. Review. J Clin Psychopharmacol 1997; 17: 208-221
39. Catterson ML, Preskorn SH. Pharmacokinetics of SSRI: Clinical Relevance. Pharmacol Tox 1996; 78: 203-208
40. Eckert A, Reiff J, Müller WE. Arzneimittelinteraktionen mit Antidepressiva. Psychopharmakotherapie 1998; 5: 8-17
41. Normann C, Hesslinger B, Bauer J et al. Die Bedeutung des hepatischen Cytochrom-P450-Systems für die Psychopharmakologie. Nervenarzt 1998; 69: 944-955
42. Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Brit J Psychiatry 1994; 164: 665-673
43. Hylan TR, Crown WH, Meneades L et al. Tricyclic antidepressants and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998; 47: 71-79
44. Lapierre Y, Bentkover J, Schainbaum S et al. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Can J Psychiatry 1995; 40: 370-377